Literature DB >> 17116217

Comparison of the growth hormone, IGF-1 and insulin in cerebrospinal fluid and serum between patients with motor neuron disease and healthy controls.

E Bilic1, E Bilic1, I Rudan, V Kusec, N Zurak, D Delimar, M Zagar.   

Abstract

Neurotrophic effects of the growth hormone (GH), insulin-like growth factor-1 (IGF-1) and insulin on the central nervous system have become more apparent in the past decade. In this study, we measured serum and cerebrospinal fluid (CSF) concentrations of GH, IGF-1 and insulin in 35 patients with motor neuron disease (MND) [24 patients with definite amyotrophic lateral sclerosis (ALS) and 11 patients with progressive bulbar palsy] and in 40 healthy controls. Levels of serum concentrations of GH and IGF-1 did not significantly differ between the MND patient group and the healthy controls, while the level of insulin was significantly decreased (P = 0.0033) in the MND patient group. However, levels of all three examined parameters in CSF were significantly lower in the MND group than in the healthy controls with the statistical significance for IGF-1 and insulin of P < 0.001. This finding has not been reported previously, and further investigations into its association with ALS should establish whether it can be used as an early marker of the disease, or whether it merely represents a consequence of ALS development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17116217     DOI: 10.1111/j.1468-1331.2006.01503.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  21 in total

Review 1.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

2.  Novel CSF biomarkers for frontotemporal lobar degenerations.

Authors:  W T Hu; A Chen-Plotkin; M Grossman; S E Arnold; C M Clark; L M Shaw; L McCluskey; L Elman; H I Hurtig; A Siderowf; V M-Y Lee; H Soares; J Q Trojanowski
Journal:  Neurology       Date:  2010-11-03       Impact factor: 9.910

Review 3.  On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia.

Authors:  F Geser; D Prvulovic; L O'Dwyer; O Hardiman; P Bede; A L W Bokde; J Q Trojanowski; H Hampel
Journal:  Prog Neurobiol       Date:  2011-09-03       Impact factor: 11.685

4.  Dipeptide repeat protein and TDP-43 pathology along the hypothalamic-pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases.

Authors:  Lieselot Dedeene; Evelien Van Schoor; Simona Ospitalieri; Alicja Ronisz; Jochen H Weishaupt; Markus Otto; Albert C Ludolph; Angelika Scheuerle; Rik Vandenberghe; Philip Van Damme; Koen Poesen; Dietmar Rudolf Thal
Journal:  Acta Neuropathol       Date:  2020-08-30       Impact factor: 17.088

Review 5.  Biomarkers in frontotemporal lobar degenerations--progress and challenges.

Authors:  William T Hu; John Q Trojanowski; Leslie M Shaw
Journal:  Prog Neurobiol       Date:  2011-04-30       Impact factor: 11.685

Review 6.  Potential new complication in drug therapy development for amyotrophic lateral sclerosis.

Authors:  Svitlana Garbuzova-Davis; Avery Thomson; Crupa Kurien; R Douglas Shytle; Paul R Sanberg
Journal:  Expert Rev Neurother       Date:  2016-07-15       Impact factor: 4.618

7.  Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly.

Authors:  Erlick A C Pereira; Martin R Turner; John A H Wass; Kevin Talbot
Journal:  Amyotroph Lateral Scler       Date:  2010

Review 8.  Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.

Authors:  Stacey A Sakowski; Adam D Schuyler; Eva L Feldman
Journal:  Amyotroph Lateral Scler       Date:  2009-04

Review 9.  Applying proteomics to the diagnosis and treatment of ALS and related diseases.

Authors:  Robert Bowser; David Lacomis
Journal:  Muscle Nerve       Date:  2009-11       Impact factor: 3.217

Review 10.  Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Miles R Bryan; Aaron B Bowman
Journal:  Adv Neurobiol       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.